Singapore: +65-31631880 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Kenya: +254-732-300719


Clinical Trial News

Promising drug combination for advanced prostate cancer

A new drug combination may be effective in treating men with metastatic prostate cancer.

Lung cancer: Adaptimmune initiates Phase I / II trial evaluating its Affinity enhanced Tcell therapy targeting NY-ESO-1

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, has announced that it has initiated a study of its affinity enhanced T-cell therapy...

Pioneering 'Science to Survive' pipeline gives cancer patients hope for a brighter future

Potentially life-saving therapies for cancer will be accelerated into clinical trials more quickly due to a pioneering project launched by scientists and clinicians at the University of Sheffield.

Autifony Therapeutics initiates Phase I study of AUT00206, a novel treatment approach for schizophrenia

Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing loss and other serious brain disorders, today announced the start of Phase I...

Genmab announces ofatumumab Phase III study in follicular lymphoma to be stopped following planned interim analysis

Genmab A/S has announced that the Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed at least 6...

VolitionRx demonstrates NUQ blood test detects lung cancers with more than 90% accuracy

VolitionRx Limited has announced interim data demonstrating its NuQ® blood tests have accurately detected more than 90% of lung cancer cases in a study of 73 patients.

Combination of pills for advanced skin cancer extends survival compared with previous monotherapy

The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.

Data show tolerability and effectiveness of SIMPONI in treating patients with active non-radiographic axial spondyloarthritis

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA), recently announced long-term tolerability and efficacy results from the open-label extension1 of the GO-AHEAD study, a randomised, double-blind...

James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook